We’re improving medication adherence
A recent study examined adherence among patients using inhaled Tyvaso (treprostinil) and found that those enrolled in CVS Specialty’s pharmacist-managed PAH program had 11.5% higher adherence rates. The proportion of days covered (PDC) was 87% vs. 78% in the control group.
The data underscores how CVS Specialty’s comprehensive, high-touch, pharmacist-led model helps patients stay on therapy longer and more consistently. Through regular medication therapy assessments and personalized support, patients are better equipped to manage their condition and avoid complications.
We deliver equitable access
Evidence from our Rare Disease Program study shows that CVS Specialty reaches patients where they are, including those in rural, diverse and underserved communities.
Of more than 7,600 CVS Specialty patients in the program, 44% lived in rural communities and 16% were from the most socially vulnerable populations, highlighting the reach and access our model offers, even in the face of the geographic and social barriers that often complicate rare disease care.
Notably, patients in the program were also deeply engaged, with nearly half completing five or more assessments and remaining enrolled for over 200 days.
“The research reflects our commitment to meeting patients where they are,” says Ashley Czonstkowsky, Vice President of Coram & CVS Specialty Therapy Operations. “It’s worth pointing out that our reach matters not only to patients, but also to payors, providers, manufacturers, and advocacy groups who rely on scalable, equitable solutions to improve care delivery.”
Data and analytics illustrate impact on quality of life
Coram CVS Specialty Infusion Services conducted a retrospective three-year quality assurance review analyzing 2,500+ dietitian-led patient interviews, giving us valuable insight on how therapy can impact a patient’s quality of life.
The patients in this study have short bowel syndrome and were taking the drug teduglutide, to reduce or eliminate their dependence on nutritional and hydration therapies — which can be both costly and confining for patients.
“While teduglutide’s clinical impact is well-documented, it doesn’t tell the whole story,” says Sarah Carter, one of the CVS Specialty registered dietitians who led the review. “Patient-reported experiences — such as feeling stronger, gaining weight or being able to travel — can reveal how the therapy affects daily life, independence and emotional well-being. It can demonstrate the broader value of these therapies.”
Most patients reported a response to therapy within the first two months, an insight especially valuable for CareTeams to set expectations, monitor progress and support patients through the early stages of treatment.
By leveraging platforms like Coram’s electronic medical records systems, our teams can track patient progress, dentify trends and personalize support. This capability allows us to better understand patient needs and deliver care that goes far beyond the prescription.
